Cargando…
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442414/ https://www.ncbi.nlm.nih.gov/pubmed/34525968 http://dx.doi.org/10.1186/s12885-021-08693-9 |
| _version_ | 1783753003084283904 |
|---|---|
| author | Powles, Thomas Choueiri, Toni K. Motzer, Robert J. Jonasch, Eric Pal, Sumanta Tannir, Nizar M. Signoretti, Sabina Kaldate, Rajesh Scheffold, Christian Wang, Evelyn Aftab, Dana T. Escudier, Bernard George, Daniel J. |
| author_facet | Powles, Thomas Choueiri, Toni K. Motzer, Robert J. Jonasch, Eric Pal, Sumanta Tannir, Nizar M. Signoretti, Sabina Kaldate, Rajesh Scheffold, Christian Wang, Evelyn Aftab, Dana T. Escudier, Bernard George, Daniel J. |
| author_sort | Powles, Thomas |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8442414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-84424142021-09-15 Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma Powles, Thomas Choueiri, Toni K. Motzer, Robert J. Jonasch, Eric Pal, Sumanta Tannir, Nizar M. Signoretti, Sabina Kaldate, Rajesh Scheffold, Christian Wang, Evelyn Aftab, Dana T. Escudier, Bernard George, Daniel J. BMC Cancer Correction BioMed Central 2021-09-15 /pmc/articles/PMC8442414/ /pubmed/34525968 http://dx.doi.org/10.1186/s12885-021-08693-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Powles, Thomas Choueiri, Toni K. Motzer, Robert J. Jonasch, Eric Pal, Sumanta Tannir, Nizar M. Signoretti, Sabina Kaldate, Rajesh Scheffold, Christian Wang, Evelyn Aftab, Dana T. Escudier, Bernard George, Daniel J. Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_full | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_fullStr | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_full_unstemmed | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_short | Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| title_sort | correction to: outcomes based on plasma biomarkers in meteor, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442414/ https://www.ncbi.nlm.nih.gov/pubmed/34525968 http://dx.doi.org/10.1186/s12885-021-08693-9 |
| work_keys_str_mv | AT powlesthomas correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT choueiritonik correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT motzerrobertj correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT jonascheric correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT palsumanta correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT tannirnizarm correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT signorettisabina correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT kaldaterajesh correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT scheffoldchristian correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT wangevelyn correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT aftabdanat correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT escudierbernard correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma AT georgedanielj correctiontooutcomesbasedonplasmabiomarkersinmeteorarandomizedphase3trialofcabozantinibvseverolimusinadvancedrenalcellcarcinoma |